Low-dose MTX appears to be as effective as CQ in patients with articular and cutaneous manifestations of SLE, having an acceptable toxicity profile. Results of this prospective study need to be confirmed in a larger study.
R.H. BryanJ.G. MerkleG. C. SmithG.D. Whitman
H. SusukidaDaizo SunamotoMasanobu SatoT. Funada